ArticleWorld journal of microbiology & biotechnology2025
Enhanced L-serine production in Corynebacterium glutamicum via promoter engineering and Bayesian optimization.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
L-serine is a valuable compound in various industries, including medicine, food and cosmetics. Corynebacterium glutamicum is the preferred choice for the fermentation production of amino acids. In this study, to enhance the L-serine titer, we engineered a C. glutamicum strain capable of high production of L-serine by regulating the transcription level of the L-serine synthesis key enzymes (serA, serC and serB). Firstly, the native promoter strengths of serA, serC and serB in strain C. glutamicum A36 (with 31.1 g/L L-serine titer) were evaluated and compared with four known-strength promoters (Pkan, dap-e, A16-1 and dap-e11). The promoter strength ratios were P-serA: P-serC: P-serB = 101.70: 1: 7.69, ranking as P-serC < Pkan < P-serB < dap-e < P-serA < A16-1 < dap-e11. Then, we regulated and enhanced the L-serine synthesis pathway by promoter engineering through two steps. In the first step, the native promoters of serA, serC and serB were replaced with stronger promoters individually, leading to 9 recombinant strains. The highest L-serine titer of A36-serA
Indexed as
Identifiers
40555934What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.